Figure 1From: The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancerThe inhibitory rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb, I131-IgG or PSCA-mAb (* P < 0.05, compared with the LNCaP cells treated with I131-PSCA-mAb; # P < 0.05, compared with the PC-3 cells treated with I131-PSCA-mAb).Back to article page